Back to Search
Start Over
Crying Time and RORγ/FOXP3 Expression in Lactobacillus reuteri DSM17938-Treated Infants with Colic: A Randomized Trial.
- Source :
-
The Journal of pediatrics [J Pediatr] 2018 Jan; Vol. 192, pp. 171-177.e1. Date of Electronic Publication: 2017 Sep 29. - Publication Year :
- 2018
-
Abstract
- Objectives: To evaluate crying time, retinoid-related orphan receptor-γ (RORγ) and forkhead box P3 (FOXP3) messenger RNA levels (transcription factors that can modulate T cell responses to gut microbes), and to investigate gut microbiota and fecal calprotectin in infants treated with Lactobacillus reuteri for infantile colic.<br />Study Design: A double-blind, placebo-controlled randomized trial was conducted in primary care in Torino from August 1, 2015 to September 30, 2016. Patients suffering from infantile colic were randomly assigned to receive daily oral L reuteri (1 × 10 <superscript>8</superscript> colony forming unit) or placebo for 1 month. Daily crying times were recorded in a structured diary. FOXP3 and RORγ messenger RNA in the peripheral blood was assessed with real-time TaqMan reverse transcription polymerase chain reaction. Gut microbiota and fecal calprotectin were evaluated.<br />Results: After infants with colic were supplemented with L reuteri DSM 17938 for 30 days, crying times were significantly shorter among infants with colic in the probiotic group compared with infants in the placebo group (74.67 ± 25.04 [IQR = 79] minutes /day vs 147.85 [IQR = 135] minutes /day [P = .001]). The FOXP3 concentration increased significantly (P = .009), resulting in decreased RORγ/FOXP3 ratios: 0.61 (IQR = 0.60) at day 0 and 0.48 (IQR = 0.28) at day 30 (P = .028). Furthermore, the probiotic increased the percentage of Lactobacillus (P = .049) and decreased fecal calprotectin (P = .0001).<br />Conclusions: Infants with colic treated with L reuteri for 30 days had a significantly decreased crying time and an increased FOXP3 concentration, resulting in a decreased RORγ/FOXP3 ratio. The treatment reduced fecal calprotectin.<br />Trial Registration: ClinicalTrials.gov: NCT00893711.<br /> (Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Biomarkers metabolism
Case-Control Studies
Colic metabolism
Colic microbiology
Colic psychology
Double-Blind Method
Feces chemistry
Feces microbiology
Female
Follow-Up Studies
Gastrointestinal Microbiome
Humans
Infant
Leukocyte L1 Antigen Complex metabolism
Male
Reverse Transcriptase Polymerase Chain Reaction
Treatment Outcome
Colic therapy
Crying
Forkhead Transcription Factors blood
Limosilactobacillus reuteri
Nuclear Receptor Subfamily 1, Group F, Member 3 blood
Probiotics therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1097-6833
- Volume :
- 192
- Database :
- MEDLINE
- Journal :
- The Journal of pediatrics
- Publication Type :
- Academic Journal
- Accession number :
- 28969887
- Full Text :
- https://doi.org/10.1016/j.jpeds.2017.08.062